Assessing kidney outcomes in childhood-onset lupus nephritis: role of National Institutes of Health-modified histological indices
Clinical and Experimental Pediatrics · 15.02.2026 · 69 (2) · 130-139
DOI: 10.3345/cep.2025.01277 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Pediatrics, erschienen am 15.02.2026. Verfasst von Nuanpan Penboon und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Childhood-onset lupus nephritis (cLN) is an aggressive disease. Although histological class has historically guided its treatment, its prognostic value remains limited. Although the National Institutes of Health (NIH)-modified activity index (AI) and chronicity index (CI) incorporate glomerular and tubulointerstitial changes and may provide better prognostic insight, their utility in cLN is not well established.
Purpose
Here we aimed to assess the utility of the NIH-modified-modified AI and CI for predicting kidney outcomes and identify histopathological features and treatment-related factors associated with the development of kidney function impairment in cLN.
Methods
We retrospectively analyzed 60 children with biopsy-proven proliferative lupus nephritis. Their baseline clinical and histological features, treatments, and outcomes were assessed. The association between AI and CI scores, along with individual histological components, and kidney function impairment, defined as an estimated glomerular filtration rate < 90 mL/min/1.73 m² sustained for ≥3 months, was evaluated.
Results
Over a median follow-up of 55.5 months, 30% of patients developed kidney function impairment. AI scores and glomerular lesions did not differ significantly between patients with and without kidney function impairment. However, the CI scores were significantly higher in patients who developed kidney function impairment, with tubular atrophy and interstitial fibrosis being the most predictive components. On a multivariate analysis, tubular atrophy was an independent predictor of kidney function impairment (hazard ratio [HR], 17.74; 95% confidence interval [CI], 1.94–162.5; P=0.01). Use of mycophenolate mofetil (MMF) as maintenance therapy was associated with a reduced risk of kidney function impairment (HR, 0.09; 95% CI, 0.02–0.47; P=0.003).
Conclusion
Chronic tubulointerstitial changes, particularly tubular atrophy, are a stronger predictor of longterm kidney function than glomerular findings or AI scores. These findings highlight the prognostic value of NIH-modified CI and the importance of MMF in maintenance therapy. The early identification of chronic lesions on biopsy may guide therapeutic decisions aimed at preserving kidney function and improving long-term outcomes in patients with cLN.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Zitieren
APA
Penboon, N., & Rianthavorn, P. (2026). Assessing kidney outcomes in childhood-onset lupus nephritis: role of National Institutes of Health-modified histological indices. Clinical and Experimental Pediatrics, 69(2), 130-139. https://doi.org/10.3345/cep.2025.01277
Vancouver
Penboon N, Rianthavorn P. Assessing kidney outcomes in childhood-onset lupus nephritis: role of National Institutes of Health-modified histological indices. Clinical and Experimental Pediatrics. 2026;69(2):130-139. doi:10.3345/cep.2025.01277
BibTeX
@article{Penboon2026,
author = {Penboon, Nuanpan and Rianthavorn, Pornpimol},
title = {Assessing kidney outcomes in childhood-onset lupus nephritis: role of National Institutes of Health-modified histological indices},
journal = {Clinical and Experimental Pediatrics},
year = {2026},
volume = {69},
number = {2},
pages = {130--139},
doi = {10.3345/cep.2025.01277}
}
EUVIMED